ALK Abelló

What ALK Abelló does

ALK-Abelló A/S is a Danish specialty pharmaceutical company founded in 1923 and headquartered in Hørsholm, Denmark, publicly traded on the Copenhagen Stock Exchange under ticker ALK B. The company focuses exclusively on the prevention, diagnosis, and treatment of allergies, operating across respiratory allergy (house dust mite, pollen), food allergy (peanut), venom allergy, anaphylaxis, and related therapy areas. ALK employs 1,001–5,000 people and serves patients and healthcare professionals across Europe, North America, the Middle East, and Asia-Pacific.

The company's core technology platforms are sublingual immunotherapy (SLIT) tablets — with 20 years of clinical experience including ODACTRA for house dust mite allergy and a peanut allergy tablet in Phase 2/3 — and the EURneffy/neffy needle-free nasal adrenaline spray licensed from ARS Pharmaceuticals for anaphylaxis emergency treatment. Revenue is generated through direct commercialization in European markets (including pediatric tablet launches and EURneffy rollout in Germany and the UK), exclusive licensing arrangements in Canada (ARS Pharma), China (GenSci), and other Asia-Pacific territories, plus consumer healthcare and diagnostic product lines. Pricing is determined nationally through reimbursement systems and is not publicly disclosed.

ALK monetizes through product sales across its SLIT franchise and the EURneffy/neffy spray, supplemented by licensing upfront and milestone payments (e.g., ARS Pharma's $155M received plus up to $310M in contingent milestones, and a GenSci upfront payment contributing to 2025 free cash flow). The company resumed dividend distributions at approximately 30% of net profit in 2025 and operates with a hybrid go-to-market combining direct European field sales with channel partners across Canada, China, Japan, Australia, and the UAE. Full-year 2025 revenue was DKK 6,312 million with 15% growth and 26% EBIT margin, and Q1 2026 revenue reached DKK 1,771 million with 18% organic growth and 32% EBIT margin.

Name

ALK Abelló

Legal name

ALK-Abelló A/S

Website

https://alk-abello.com

Company type

Public

Founded year

1923

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company founded in 1923 that develops and commercializes sublingual immunotherapy tablets and a needle-free nasal adrenaline spray for allergy prevention, diagnosis, and treatment, serving patients and clinicians across Europe, North America, the Middle East, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Allergy Immunotherapy Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)

akta.pro secondary industries

Respiratory & Allergy Pharmaceuticals (HLAIAAAH), Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

Keywords

• Allergy immunotherapy
• Sublingual immunotherapy tablets
• Nasal adrenaline spray
• Allergy diagnostics
• Anaphylaxis treatment

Headquarters

HQ city

Hørsholm

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Allergy Immunotherapy Tablets: ALK generates revenue primarily from the sale of sublingual immunotherapy (SLIT) tablets for treating respiratory allergies (house dust mite, pollen) and food allergies (peanut). In Q1 2026, total tablet sales exceeded DKK 1 billion in a single quarter for the first time. The company resumed dividend payments at DKK 355 million (approximately 30% of net profit after tax) for 2025.
2. EURneffy / neffy Nasal Adrenaline Spray: Revenue from commercialization of the needle-free nasal adrenaline spray EURneffy in Europe and licensed neffy in Canada. ALK holds exclusive licensing rights to commercialize neffy in Canada, with ARS Pharma having received $155 million in upfront and milestone payments and eligible for up to $310 million in additional regulatory and sales milestones. The spray is available in 1 mg and 2 mg strengths.
3. Licensing and Partnership Payments: ALK receives upfront payments and milestone payments from licensing partnerships, including a new Chinese partnership with GenSci that generated an upfront payment contributing to strong free cash flow of DKK 1,432 million in 2025.
4. Consumer Healthcare Products: Revenue from consumer healthcare products including diagnostics and related therapy area products, as referenced in the company's product portfolio and disease area coverage.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

ALK develops, manufactures, and commercializes allergy immunotherapy products spanning the full allergy care continuum. Its core offering is a portfolio of sublingual immunotherapy (SLIT) tablets (including ODACTRA for house dust mite allergy) for respiratory and food allergies, paired with allergy diagnostic assays and consumer healthcare products. The company has expanded into acute anaphylaxis treatment through EURneffy / neffy, the only regulatory-approved needle-free nasal adrenaline spray available in multiple strengths for adults and children.

Product overview

ALK Abelló is a global specialty pharmaceutical company headquartered in Hørsholm, Denmark, focused on allergy diagnostics and treatments. The company offers a diversified portfolio of sublingual immunotherapy (SLIT) tablets for respiratory allergies (house dust mite, pollen) and food allergies (peanut), alongside neffy®/EURneffy, a needle-free nasal adrenaline spray for anaphylaxis emergency treatment. ALK's product portfolio spans the allergy care continuum from diagnosis through treatment, with its SLIT tablet franchise representing its core platform and neffy representing an expansion into anaphylaxis management. The company operates across all major markets through direct commercialization and licensing partnerships.

Differentiator

Problem solved

Functional benefit

Products and services

• EURneffy / neffy (Nasal Adrenaline Spray) Needle-free nasal adrenaline spray for emergency treatment of anaphylaxis in adults and children. Available in 2 mg (U.S., Canada) and 1 mg (EU, UK, UAE) strengths. 88% of users prefer it over auto-injectors due to portability, ease of use, and less stigmatizing appearance.
• Sublingual Immunotherapy (SLIT) Tablets ALK's flagship portfolio of sublingual immunotherapy tablets for treating respiratory allergies (house dust mite, pollen) and food allergies, built on 20 years of clinical experience and the primary platform behind total tablet sales exceeding DKK 1 billion in Q1 2026.
• ODACTRA House dust mite sublingual immunotherapy tablet marketed by ALK, FDA-approved and with an expanded pediatric indication for children aged 5-11.
• Allergy Diagnostics Allergy diagnostic assay kits and testing products used by allergists and clinicians to identify specific allergens affecting patients, supporting targeted SLIT immunotherapy prescribing decisions.
• Consumer Healthcare Products Consumer healthcare products for allergy management and treatment, sold as part of ALK's broader allergy care continuum covering both prescription pharmaceuticals and over-the-counter allergy offerings.

Quantifiable outcome

• 49% of patients tolerated 300 mg of peanut protein versus 18% on placebo (p<0.001) after 24 weeks of maintenance treatment at highest dose in Phase 2 trial
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• GenSci (China)coreStrategic or Co-development Partner · 1 January 2025ALK entered a new Chinese partnership with GenSci for the commercialization of its allergy immunotherapy products in China. The partnership generated an upfront payment contributing to strong free cash flow of DKK 1,432 million in 2025, representing a significant strategic expansion into the Chinese market.
• ARS PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 November 2024ALK-Abelló holds exclusive licensing rights to commercialize neffy, the epinephrine nasal spray developed by ARS Pharmaceuticals, in Canada. ARS Pharma received $155 million in upfront and milestone payments from ALK and is eligible for up to $310 million in additional regulatory and sales milestones. neffy was approved by Health Canada in April 2026 with expected launch in summer 2026.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Viatris (EpiPen): Global pharmaceutical company and maker of EpiPen, the dominant branded epinephrine auto-injector. Direct competitor to EURneffy/neffy in the emergency anaphylaxis treatment market.
• Sanofi: Global pharmaceutical major with significant respiratory and allergy franchises, including dupilumab (Dupixent) for allergic conditions and historical allergen immunotherapy products. Larger competitor influencing allergy market access and reimbursement frameworks.
• Merck KGaA (Allergopharma): German life-sciences company whose Allergopharma division develops and markets allergen immunotherapy (SCIT/SLIT) products. Competes with ALK in European allergen desensitization and uses broader Merck resources to scale distribution.

Emerging players

• Aimmune Therapeutics (Nestlé Health Science): Developer of Palforzia, the first FDA-approved oral immunotherapy for peanut allergy, now part of Nestlé Health Science. Competes with ALK's Phase 2 peanut SLIT tablet in the food allergy desensitization market.
• DBV Technologies: Clinical-stage biotech developing Viaskin epicutaneous immunotherapy (peanut, milk) for food allergies. Competes with ALK's emerging SLIT-tablet peanut franchise in the food allergy desensitization space.
• Stada Arzneimittel: European specialty pharmaceutical company with growing focus on allergen immunotherapy and allergy consumer healthcare products. Competes with ALK in selected European markets in the allergy space.

Direct peers

• Allergy Therapeutics: UK-based specialty pharmaceutical company developing and marketing allergen-specific immunotherapy products (Pollinex Quattro, Venomil) for allergic disease treatment. Competes directly with ALK in the European allergen immunotherapy market.
• Stallergenes Greer: Global specialty allergen immunotherapy company offering both subcutaneous (SCIT) and sublingual (SLIT) treatments for respiratory allergies. Closest direct competitor to ALK in the allergen immunotherapy tablet space and overlapping prescriber base of allergists worldwide.
• HAL Allergy: European allergen immunotherapy specialist offering diagnostic and immunotherapy products (subcutaneous and sublingual) for pollen, mite, and venom allergies. Direct competitor in European markets where ALK's SLIT tablets are launched.
• ARS Pharmaceuticals: Developer of neffy (epinephrine nasal spray) and ALK's licensor for European/Canadian commercialization. Highly coupled peer via the EURneffy licensing arrangement — same needle-free epinephrine product, different geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alk-abello
• Xx.com/ALK_net

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALK Abelló